Screening for Hepatocellular Carcinoma in Patients with Cirrhosis
Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis who underwent imaging with either ultrasound, contrast enhanced CT or MRI for hepatocellular carcinoma (HCC) at least once within the 12 month reporting period.
-
Group/Practice
Individual Clinician
Measure Info
ACP does not support QPP measure 401: "Hepatitis C: Screening for Hepatocellular Carcinoma" because the screening benefits do not outweigh the substantial risks of harms related to radiation exposure and treatment of incidental findings. Furthermore, developers cite weak evidence to form the basis of the measure. A recent evidence review demonstrates insufficient evidence for screening for hepatocellular carcinoma among patients with cirrhosis.